Gadoteridol ( DrugBank: Gadoteridol )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03396822 (ClinicalTrials.gov)	September 24, 2018	4/1/2018	Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis	Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis	Multiple Sclerosis	Drug: Gadoteridol	University of Maryland, Baltimore	Genentech, Inc.	Active, not recruiting	18 Years	65 Years	All	24		United States
2	NCT02481882 (ClinicalTrials.gov)	January 2017	19/5/2015	Baseline Cortical Haemodynamics in MS	Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis	Multiple Sclerosis	Device: Magnetic Resonance Imaging;Drug: Prohance (Gadoteridol)	University of Nottingham	NULL	Unknown status	21 Years	80 Years	All	80	N/A	United Kingdom